Tolerability of Enteral NAC in Infants

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Biliary Atresia
Interventions
DRUG

N-Acetylcysteine

"This is a phase 1 study of tolerance of a novel delivery method of oral NAC medication in infants with biliary atresia. The study consists of two parts:~* Administering applesauce alone (lead-in): In study days 1-2, infants will receive one infant spoon (approximately ½ teaspoon) of plain applesauce by mouth twice a day. If the infant tolerates 3-4 of 4 total doses without emesis, the infant will progress to the final two days of the study.~* Administering applesauce plus NAC (for infants who tolerate applesauce in study days 1-2): In study days 3-4, infants will receive an individualized dose of powdered oral NAC mixed into one infant spoon of applesauce by mouth twice a day for a maximum of four doses of NAC medication. 4 doses will be trialed: 150 mg/kg/day, 240 mg/kg/day, 330 mg/kg/day, and 420 mg/kg/day using BOIN study design for dose escalation."

All Listed Sponsors
collaborator

Baylor College of Medicine

OTHER

lead

Sanjiv Harpavat

OTHER

NCT06260566 - Tolerability of Enteral NAC in Infants | Biotech Hunter | Biotech Hunter